Resources
BNET Resources
- sort by:
- Relevance
- Date
- Popularity
- Serada Half Price Sale: DepoMed's Stock Price Poised to Climb
- Three Brothers Health submits: Several weeks ago, DepoMed (NASDAQ:DEPO), a specialty pharmaceutical company, announced positive phase 3 trial results for the treatment of Post Herpetic Neuralgia (‘PHN’) with DM1796. But DepoMed’s news of success was soon eclipsed. Only one week later, the company announced that Serada didn’t meet...
- External links 2009-11-08
- << Previous
- page 1 of 1
- Next >>
